Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 470 participants.

Also called NCT01395823

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 470 participants (enrolled count) (from the registry)
Sponsor
Dialysis Clinic, Inc. (from the registry)
Registry
  • NCT NCT01395823
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01395823. Randomized; quadruple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2016-03-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Condition
End Stage Renal Disease
Intervention (Dietary supplement)
ergocalciferol supplementation
Intervention (Other)
placebo
Lead sponsor
Dialysis Clinic, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01395823
Content hash
0c143b7704deb8d242491208c11fd78064667bdb7c2e8875f9402027db52d86e